Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 11, 2025P A Herzen Journal of Oncology

Prognostic value of positron emission tomography-derived metabolic tumor volume for the efficacy of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

PDP. D. DziameshkaN.N. Alexandrov National Cancer CentreNKN. E. KonoplyaWeatherford CollegeVKV. A. KalenikWeatherford College

Discussion

Loading...

Member takes

Implication

Analysis reveals metabolic tumor volume impacts progression-free survival in non-Hodgkin lymphoma patients treated with CAR T-cell therapy, suggesting predictive value.

Key Points

  • To evaluate the impact of metabolic tumor volume on treatment outcomes in non-Hodgkin lymphoma patients receiving CAR T-cell therapy.
  • Retrospective analysis of metabolic tumor volume in 20 non-Hodgkin lymphoma patients
  • Assessment using PET-CT imaging before treatment
  • Calculation of semi-automatically segmented metabolic volume and weight-standardized metabolic volume.
  • Median metabolic tumor volume was 99.4 mL and weight-standardized metabolic volume was 1.6 mL/kg
  • 1-year progression-free survival was 17.9% for high metabolic tumor volume and 90.9% for low weight-standardized metabolic volume
  • 1-year overall survival was 17.9% for high metabolic tumor volume and 100% for low weight-standardized metabolic volume.

Cite This Study

Dziameshka et al. (2025) studied this question.

synapsesocial.com/papers/69401b0d2d562116f28f7061https://doi.org/10.17116/onkolog20251406113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma2020 · 255 citations
  3. 3ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells2018 · 3,694 citations
  4. 4WHO classification of tumors of hematopoietic and lymphoid tissues, 2022 (5th edition): lymphoid tumors2023 · 24 citations
  5. 5Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index2022 · 164 citations